Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes

Poul Strange1

  • 1Poul Strange Consulting LLC, Princeton Junction, New Jersey 08550, USA. pstrange@verizon.net

Abstract

Insights

Insulin titration algorithms improve glycemic control in type 2 diabetes. These systematic approaches to insulin dosing enhance patient outcomes with minimal risk of hypoglycemia when fasting glucose targets are maintained above 100 mg/dl.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Traditional insulin titration in type 2 diabetes trials lacked standardization, often resulting in suboptimal glycemic control.
  • Recent advancements include the use of various insulin titration algorithms in clinical trials.

Purpose of the Study:

  • To review the evidence on insulin titration algorithms in type 2 diabetes management.
  • To assess the effectiveness and safety of different algorithms.

Main Methods:

  • Literature search of PubMed using keywords "insulin and titration" and "insulin and algorithm".
  • Selection of studies involving insulin titration algorithms for type 2 diabetes initiation.

Main Results:

  • Review of diverse algorithms, their impact on glycemic control, and hypoglycemia rates.
  • Identification of factors influencing algorithm outcomes.

Conclusions:

  • Rigorously implemented insulin titration algorithms significantly improve glycemic control in type 2 diabetes patients on oral medications.
  • These algorithms offer better outcomes with low risk of severe hypoglycemia, provided fasting plasma glucose targets are not below 100 mg/dl.
  • Insulin titration algorithms are evolving towards greater patient involvement and control.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...